Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Hand-Foot Syndrome 2Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms, Male 2Rectal Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Cancer Related Fatigue 1

Interventions

Paclitaxel 25Doxorubicin 15Carboplatin 14pembrolizumab 10Cisplatin 8Radiotherapy 6Docetaxel 5Chemotherapy, Adjuvant 5Taxes 4Filgrastim 4Brachytherapy 4lenvatinib 3Observation 3trastuzumab deruxtecan 2selinexor 2olaparib 2durvalumab 2Tamoxifen 2Specimen Handling 2Ifosfamide 2Drug Therapy 2sintilimab 1sacituzumab govitecan 1pertuzumab 1nanocis 1liposomal doxorubicin 1ixabepilone 1gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1dostarlimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Endometrial Neoplasms × Pyridoxine × Clear all
NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Case Comprehensive Cancer Center

Phase 3 Completed
34 enrolled 9 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡